CIMG Inc. Expands Horizons with Acquisition of Daren Technology
CIMG Inc. (NASDAQ: IMG) has made significant strides in the biopharmaceutical sector by entering into an agreement to acquire Daren Business Technology Limited. This pivotal move comes as CIMG, a well-respected business group specializing in digital health and sales development, seeks to diversify its portfolio and enhance its commercial value through innovative technologies and marketing strategies.
Details of the Acquisition Agreement
CIMG's wholly owned subsidiary, DZR Tech Limited, has signed a definitive share purchase agreement with Daren Business Technology Limited. The acquisition is set to encompass 100% of Daren's issued equity interests, positioning CIMG to strengthen its foothold within a rapidly evolving industry. The completion of this transaction is contingent upon customary closing conditions and thorough due diligence.
Executing this purchase involves an aggregate consideration estimated at approximately $40 million, which will be paid through shares held in escrow. This process will span about 3.5 years, where the release of these escrowed shares is dependent on Daren meeting specific performance targets. The performance evaluation periods extend from April 2026 to September 2029, with the release percentages categorized into four distinct phases.
Performance Benchmarks Set for Daren
CIMG has outlined ambitious revenue benchmarks for Daren's performance across various assessment periods. Under this agreement, the first phase requires the company to achieve an audited revenue of at least $29 million within six months post-acquisition. This revenue target escalates in subsequent years, with the final assessment aiming for no less than $257 million by 2029.
However, any period where Daren falls short of its performance targets may lead to a reduction in the escrowed shares allocated for that specific timeframe, reinforcing CIMG's commitment to making performance-driven investments. Moreover, if Daren performs well beyond expectations, it could help mitigate any shortfalls from earlier assessments, ensuring mutual benefit.
Daren’s Role in Biomedicine
Daren Business Technology Limited stands as a high-tech entity dedicated to advancing biomedicine. The company's mission emphasizes enhancing quality of life through innovation, underlining its commitment to research, development, and comprehensive service delivery in the biomedical field. With a strong focus on integration across R&D, production, and marketing, Daren is poised to deliver medical products and solutions that address evolving health needs.
Strategic Vision for Future Growth
Alice Wang, the Chairwoman and CEO of CIMG, expressed that this acquisition marks a pivotal step towards diversifying the company’s operations and establishing a significant presence in the biopharmaceutical market. She emphasizes the necessity of increasing investments in this rapidly growing sector, leveraging advanced technologies to create new opportunities for growth.
About CIMG Inc.
CIMG Inc. is a forward-thinking business group centered around digital health and sales development. With a keen interest in utilizing AI and cryptocurrency strategies, CIMG aims to foster growth and enhance client brand value in innovative ways. The company has developed a diverse portfolio, engaging clients across various industries such as healthcare and wellness.
Frequently Asked Questions
What is the significance of CIMG acquiring Daren Business Technology Limited?
This acquisition represents CIMG's strategic entry into the biopharmaceutical industry, promoting diversification and innovation.
How will CIMG pay for the Daren acquisition?
CIMG will compensate for the acquisition through shares held in escrow, with a total value of around $40 million released based on performance metrics.
What are the performance targets set for Daren?
Daren is required to achieve specific audited revenue milestones over set periods, ranging from $29 million up to $257 million across several years.
What does Daren specialize in?
Daren is focused on biomedicine, integrating R&D, production, and marketing to deliver healthcare solutions aimed at enhancing human well-being.
Who is the CEO of CIMG Inc.?
Alice Wang serves as the Chairwoman and CEO, promoting the vision of expanding into the promising biopharmaceutical sector.
